OPPG与高骨量疾病的临床特征、治疗及随访:LRP5是骨量的关键调节因子
本研究纳入2例骨质疏松-假性胶质瘤综合征(OPPG)患者和4例LRP5高骨量(LRP5-HBM)患者,总结其临床表现、致病突变、治疗及随访。OPPG主要表现为先天性失明、持续骨痛、低骨密度和多发性脆性骨折,双膦酸盐治疗后骨密度显著改善;LRP5-HBM表现为极高骨密度无骨折、腭隆凸和视力正常,1例患者随访12年后出现年龄相关骨丢失。
要点
- OPPG主要表现为先天性失明、持续骨痛、低骨密度和多发性脆性骨折,双膦酸盐治疗可显著改善骨密度。
- LRP5-HBM表现为极高骨密度无骨折、腭隆凸和视力正常,X线示弥漫性骨硬化。
- 1例LRP5-HBM患者随访12年后出现年龄相关骨丢失,Ala242Thr突变未能保护其免于年龄相关骨丢失。
核心结论
- 本研究加深了对OPPG和LRP5-HBM临床特征、治疗及随访的认识,扩展了OPPG的致病基因谱,并证实双膦酸盐对OPPG有效。
- 研究发现Ala242Thr突变不能保护LRP5-HBM患者免于年龄相关骨丢失,此现象值得进一步研究。
研究设计与样本
- 本研究纳入2例OPPG患者和4例LRP5-HBM患者,总结其临床特征、生化和影像学检查、致病突变及结构分析,并对部分患者进行随访以观察治疗效果和疾病进展。
主要发现
- OPPG的主要临床表现为先天性失明、持续骨痛、低骨密度和多发性脆性骨折,2例OPPG患者检测到复合杂合突变,其中第7外显子的c.1455G>T突变为首次报道。
- 随访期间,2例OPPG患者经双膦酸盐治疗后骨密度显著改善。
- LRP5-HBM的典型临床特征包括极高骨密度无骨折、腭隆凸和视力正常,X线显示弥漫性骨硬化,4例患者中检测到2种杂合错义突变。
- 1例LRP5-HBM患者随访12年后发现年龄相关骨丢失。
局限性
- 原文指出Ala242Thr突变不能保护LRP5-HBM患者免于年龄相关骨丢失这一现象值得进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Osteoporosis-pseudoglioma syndrome (OPPG) and LRP5 high bone mass (LRP5-HBM) are two rare bone diseases with opposite clinical symptoms caused by loss-of-function and gain-of-function mutations in LRP5. Bisphosphonates are an effective treatment for OPPG patients. LRP5-HBM has a benign course, and age-related bone loss is found in one LRP5-HBM patient. PURPOSE: Low-density lipoprotein receptor-related protein 5 (LRP5) is involved in the canonical Wnt signaling pathway. The gain-of-function mutation leads to high bone mass (LRP5-HBM), while the loss-of-function mutation leads to osteoporosis-pseudoglioma syndrome (OPPG). In this study, the clinical manifestations, disease-causing mutations, treatment, and follow-up were summarized to improve the understanding of these two diseases. METHODS: Two OPPG patients and four LRP5-HBM patients were included in this study. The clinical characteristics, biochemical and radiological examinations, pathogenic mutations, and structural analysis were summarized. Furthermore, several patients were followed up to observe the treatment effect and disease progress. RESULTS: Congenital blindness, persistent bone pain, low bone mineral density (BMD), and multiple brittle fractures were the main clinical manifestations of OPPG. Complex heterozygous mutations were detected in two OPPG patients. The c.1455G > T mutation in exon 7 was first reported. During the follow-up, BMD of two patients was significantly improved after bisphosphonate treatment. On the contrary, typical clinical features of LRP5-HBM included extremely high BMD without fractures, torus palatinus and normal vision. X-ray showed diffuse osteosclerosis. Two heterozygous missense mutations were detected in four patients. In addition, age-related bone loss was found in one LRP5-HBM patient after 12-year of follow-up. CONCLUSION: This study deepened the understanding of the clinical characteristics, treatment, and follow-up of OPPG and LRP5-HBM; expanded the pathogenic gene spectrum of OPPG; and confirmed that bisphosphonates were effective for OPPG. Additionally, it was found that Ala242Thr mutation could not protect LRP5-HBM patients from age-related bone loss. This phenomenon deserves further study.
引用
- Ren N, Lv S, Li X, et al. Clinical features, treatment, and follow-up of OPPG and high-bone-mass disorders: LRP5 is a key regulator of bone mass. Osteoporos Int. 2024. PMID: 38625381. doi:10.1007/s00198-024-07080-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。